United States-based CVS Health (NYSE: CVS) is to provide COVID-19 vaccinations to long-term care facilities throughout the United States when a vaccine becomes available, it was reported on Friday.
CVS Health says that it has the experience and expertise to play a vital role in the COVID-19 vaccination effort. It quickly mobilised its colleagues and resources to provide COVID-19 testing sites in the country and have now administered over five million COVID tests.
Troyen Brennan, MD, chief medical officer, CVS Health, said, 'CVS Health has been on the front lines of the fight against COVID-19, working across the health care spectrum in all the communities we serve and that will continue to be the case when we have a vaccine to administer. Our nation's elderly living in long-term care facilities are one of the most vulnerable populations. With early access to a vaccination, we can help keep them, and the staff caring for them, healthy and safe.'
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Anixa Biosciences begins US FDA approved IND transfer to support Phase 2 breast cancer vaccine trial
Pfizer and BioNTech receive EU regulatory backing for LP.8.1-adapted COVID-19 vaccine
Sanofi to acquire Vicebio for USD1.15bn to strengthen respiratory vaccine pipeline
Bavarian Nordic chikungunya vaccine enters Health Canada review process
SK bioscience submits IND for Phase 1/2 clinical trial of new influenza vaccine candidate
GC Biopharma secures Vietnamese approval for varicella vaccine BARYCELA
GSK announces submission of RSV vaccine Arexvy for FDA review
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Centivax raises USD45m to commercialise universal flu vaccine
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results